Skip to main content

Table 2 Clinical characteristics of Parkinson’s disease patients with mild to moderate and severe non-motor symptoms burden

From: Sleep disturbances and gastrointestinal dysfunction are associated with thalamic atrophy in Parkinson’s disease

 

PD mild to moderate NMS burden (NMSS = 0–40)

PD severe NMS burden (NMSS ≥ 41)

No (%)

23 (56.1%)

18 (43.9%)

Gender (M, %)

15 (65.2%)

9 (50%)

Age (years; median ± SD)

58.5 ± 8.9

70.3 ± 8.3*

Disease durationa (months; median ± SD)

16.1 ± 60.4

108.0 ± 73.8*

Daily LED (mg; median ± SD)

250.3 ± 438.3

690.0 ± 1219.6*

H&Y OFF (median ± SD)

1.0 ± 0.8

2.3 ± 1.2*

MMSE (median ± SD)

30.0 ± 1.6

29.5 ± 1.3

PDQ-39 (median ± SD)

9.5 ± 16.1

47.0 ± 24.4***

  1. H&Y Hoehn & Yahr, LED levodopa equivalent dose, MMSE mini mental status examination, NMSS Non-motor Symptoms Scale, PDQ-39 39-item Parkinson’s disease Questionnaire, UPDRS-III Unified Parkinson’s Disease Rating Scale part III
  2. *P < 0.05; ***P < 0.001
  3. aFrom time of first appearance of Parkinson’s disease motor symptoms
Back to article page

BMC Neuroscience

ISSN: 1471-2202

Contact us